Takeda enters global strategic partnership with Innovent Biologics to bolster oncology pipeline with next-generation investigational medicines for treatment of solid tumors

CAR-T Digest - August 2020

Weekly Digest - October 2025

21 October 2025: Takeda enters global strategic partnership with Innovent Biologics to bolster oncology pipeline with next-generation investigational medicines for treatment of solid tumors

Takeda entered a global strategic partnership with Innovent Biologics to strengthen its oncology pipeline, gaining worldwide rights (excluding Greater China) to two late-stage assets IBI363, a bispecific antibody fusion protein, and IBI343, a Claudin 18.2-targeting ADC with an option to license early-stage IBI3001
The collaboration positions Takeda to expand leadership in solid tumours, with IBI363 advancing into a global Phase 3 trial in second-line sqNSCLC and IBI343 targeting high-need gastric and pancreatic cancers, both holding FDA fast track designations
Under the deal, Takeda will co-develop and co-commercialize IBI363 in the U.S and hold exclusive rights ex-U.S., while fully owning development and commercialization of IBI343 globally outside Greater China
Takeda will establish U.S.-based manufacturing for these assets to secure global supply and accelerate potential commercialization, reinforcing long-term oncology growth prospects beyond 2030
The agreement includes a US$1.2 billion upfront payment (including a $100M equity investment in Innovent), with additional milestone and royalty payments, highlighting Takeda’s strategic investment in next-generation immuno-oncology and ADC modalities to drive portfolio diversification and future growth